Arashnia Rana, Roohi-Gilani Kobra, Karimi-Sari Hamidreza, Nikjoo Niloofar, Bahramifar Ali
Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid-Beheshti University of Medical Sciences, Tehran, Iran.
Students' Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
J Nephropathol. 2015 Apr;4(2):48-53. doi: 10.12860/jnp.2015.10. Epub 2015 Apr 1.
Inflammation has a major role in disease lead to renal failure and diabetes mellitus, controlling inflammation in diabetic kidney receivers could decrease morbidity and mortality.
This study designed for evaluating the efficacy of pioglitazone on C-reactive protein and lipid profile in diabetic kidney transplant receivers.
In this double blinded clinical trial, 58 diabetic renal transplant receivers, in first month after transplantation, randomized into two groups; receiving insulin and pioglitazone (15 mg tablet daily, group A); and insulin and placebo (group B). Blood pressure, weight, body mass index (BMI) and laboratory data compared in before and after 4-month treatment in two groups by SPSS.
Fifty-eight patients with mean age of 44.15 ± 2 years included. There were no significant difference between groups in demographic data and other baseline measured variables (P > 0.05) .The mean weigh and BMI were slightly increased in group A and decreased in group B. The mean hs-CRP was decreased 4.82 mg/dL in group A and 1.93 mg/dL in group B (P = 0.007). The mean total serum cholesterol was significantly decreased 34 mg/dL in group A and 18.07 mg/dL in group B (P = 0.027). The mean serum HDL-C was significantly increased 13.31 mg/dL in group A and 5.89 mg/dl in group B (P < 0.001).
Pioglitazone seems to be a safe drug for reducing serum lipids and CRP in kidney transplant receivers with diabetes mellitus in short term. Long term effect of this drug could be evaluated in future studies.
炎症在导致肾衰竭和糖尿病的疾病中起主要作用，控制糖尿病肾病患者的炎症可降低发病率和死亡率。
本研究旨在评估吡格列酮对糖尿病肾移植受者C反应蛋白和血脂谱的疗效。
在这项双盲临床试验中，58名糖尿病肾移植受者在移植后的第一个月被随机分为两组；一组接受胰岛素和吡格列酮（每日15毫克片剂，A组）；另一组接受胰岛素和安慰剂（B组）。采用SPSS对两组患者治疗4个月前后的血压、体重、体重指数（BMI）和实验室数据进行比较。
纳入58例平均年龄为44.15±2岁的患者。两组在人口统计学数据和其他基线测量变量方面无显著差异（P>0.05）。A组的平均体重和BMI略有增加，B组则有所下降。A组的平均高敏C反应蛋白降低了4.82毫克/分升，B组降低了1.93毫克/分升（P=0.007）。A组的平均总血清胆固醇显著降低了34毫克/分升，B组降低了18.07毫克/分升（P=0.027）。A组的平均血清高密度脂蛋白胆固醇显著升高了13.31毫克/分升，B组升高了5.89毫克/分升（P<0.001）。
吡格列酮似乎是一种安全的药物，短期内可降低糖尿病肾移植受者的血脂和C反应蛋白。该药物的长期效果有待未来研究评估。
